Development of surfactin-based nanocarrier for targeted doxorubicin delivery

Bibliographic Information
Authors: Mahareek O.; Mousa N.O.; Mamdouh S.; El-Zayat E.M.; Okasha H.
Journal: Scientific Reports
Publisher: Nature Research
Publication Date: 13 June 2026
Volume / Issue: Volume 16 / Issue 1
Article No.: 18364
ISSN: 20452322
DOI: 10.1038/s41598-026-54757-w
Scopus: View on Scopus
PubMed: 42288537
Document Type: Article
Access: All Open Access; Gold Open Access; Green Open Access
Authors and Affiliations
Mahareek O., Department of Biochemistry and Molecular Biology, Theodor Bilharz Research Institute, Giza, Egypt; Mousa N.O., Department of Biotechnology, Faculty of Science, Cairo University, Giza, Egypt; Mamdouh S., Department of Biochemistry and Molecular Biology, Theodor Bilharz Research Institute, Giza, Egypt; El-Zayat E.M., Department of Biotechnology, Faculty of Science, Cairo University, Giza, Egypt; Okasha H., Department of Biochemistry and Molecular Biology, Theodor Bilharz Research Institute, Giza, Egypt
Abstract
Surfactin, one of the most powerful lipopeptide biosurfactants produced by Bacillus subtilis, has great potential for biomedical applications. Isolation, purification, and characterization of surfactin from Bacillus subtilis 6633 to be used as a doxorubicin (Dox) nanocarrier. Purified surfactin using different chromatographic columns was used to prepare a self-assembled nanocarrier for Dox, which was characterized for size, charge, and drug-loading efficiency. Biological activity against normal fibroblast (FB) and liver cancer (HepG2) cells was assessed. The hybrid nanoparticles showed a remarkable drug loading; 36%, a pH-responsive release profile with enhanced cytotoxicity toward HepG2 cells (IC₅₀ = 5.40 µg/mL), and a reduced toxicity to FB cells (IC₅₀ = 12.78 µg/mL). The nanoparticles were spherical in shape (100 ± 2 nm) with a polydisperse index of (0.019 ± 0.01) and a narrow size distribution pattern. The results support the potential of surfactin-based nanoparticles to act as a selective platform for anticancer drug delivery and underscore their relevance towards the Sustainable Development Goal 3 (Good Health and Well-being) through the development of safer and effective therapeutic strategies. © The Author(s) 2026.
Keywords
Antibacterial; Anticancer; Bacillus subtilis; Lipopeptide; Surfactin; Antineoplastic Agents; Biosurfactants; Cell Survival; Doxorubicin; Drug Carriers; Drug Delivery Systems; Hep G2 Cells; Humans; Lipopeptides; Nanoparticles; Particle Size; Peptides, Cyclic; antineoplastic agent; biosurfactant; cyclopeptide; drug carrier; nanoparticle; surfactin peptide; chemistry; drug delivery system; drug effect; Hep-G2 cell line; human; isolation and purification; metabolism
Citation Information
Scopus Citations: 0
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
